Nengming Lin
Impact in
- Infectious Diseases top 5%
- COVID-19 Clinical Research Studies
- Antifungal resistance and susceptibility
- Antimicrobial Resistance in Staphylococcus
- Oncology top 10%
- Inflammatory Biomarkers in Disease Prognosis
Papers in
-
- PI3K/AKT/mTOR signaling in cancer 6
- RNA modifications and cancer 4
- Epigenetics and DNA Methylation 4
- Oncology 23
- Cancer Treatment and Pharmacology 4
- Co-authors
- Changcheng Shi (12 shared papers)Qingyu Li (8 shared papers)Dan Su (3 shared papers)Bo Zhang (8 shared papers)Yaping Xie (6 shared papers)Junbo Xia (5 shared papers)Yubo Xiao (2 shared papers)Liming Sheng (1 shared paper)
- Journals
- Drug Metabolism and Disposition (3 papers)Frontiers in Pharmacology (3 papers)Autophagy (2 papers)International Journal of Antimicrobial Agents (2 papers)British Journal of Pharmacology (2 papers)
- Partner nations
- ChinaCzechiaUnited States
In The Last Decade
Nengming Lin
77 papers receiving 1.3k citations
Peers
Comparison fields: 5 of 123
- Infectious Diseases 251
- Oncology 284
- Cancer Research 129
- Molecular Medicine 41
- Clinical Biochemistry 56
Countries citing papers authored by Nengming Lin
This map shows the geographic impact of Nengming Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nengming Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nengming Lin more than expected).
Fields of papers citing papers by Nengming Lin
This network shows the impact of papers produced by Nengming Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nengming Lin. The network helps show where Nengming Lin may publish in the future.
Co-authors
The 25 scholars most cited alongside Nengming Lin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 81 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 111 | |
| 2 | 2013 | 94 | |
| 3 | 2020 | 63 | |
| 4 | 2013 | 60 | |
| 5 | 2019 | 55 | |
| 6 | 2021 | 44 | |
| 7 | 2022 | 39 | |
| 8 | 2018 | 39 | |
| 9 | 2015 | 39 | |
| 10 | 2015 | 37 | |
| 11 | 2022 | 33 | |
| 12 | 2014 | 31 | |
| 13 | 2018 | 31 | |
| 14 | 2022 | 29 | |
| 15 | 2021 | 28 | |
| 16 | 2021 | 24 | |
| 17 | 2018 | 23 | |
| 18 | Determination of gemcitabine and its metabolite in human plasma using high-pressure liquid chromatography coupled with a diode array detector. | 2004 | 23 |
| 19 | 2019 | 22 | |
| 20 | 2022 | 21 |
About Nengming Lin
Nengming Lin is a scholar working on Molecular Biology, Oncology, Epidemiology, Infectious Diseases and Pulmonary and Respiratory Medicine, having authored 81 papers that have together received 1.3k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (6 papers), Antimicrobial Resistance in Staphylococcus (5 papers), Cancer Treatment and Pharmacology (4 papers), Hepatitis B Virus Studies (4 papers), RNA modifications and cancer (4 papers), Autophagy in Disease and Therapy (4 papers), Ferroptosis and cancer prognosis (4 papers) and Epigenetics and DNA Methylation (4 papers). The work is most often cited by research in Infectious Diseases (251 citations), Oncology (284 citations), Cancer Research (129 citations), Molecular Medicine (41 citations) and Clinical Biochemistry (56 citations). Nengming Lin has collaborated with scholars based in China, Czechia and United States. Frequent co-authors include Changcheng Shi, Qingyu Li, Dan Su, Bo Zhang, Yaping Xie, Junbo Xia, Yubo Xiao, Liming Sheng, Xiaojiang Sun and Weimin Mao. Their work appears in journals such as Drug Metabolism and Disposition, Frontiers in Pharmacology, Autophagy, International Journal of Antimicrobial Agents and British Journal of Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.